Business
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy Strasbourg, France, January 9, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the preprint publication on medRxiv of a comprehensive analysis of both the clinical and translation
About this update from Transgene Sa
[{"type":"image","alt":"Transgene S.A.","displaySize":"","headline":null,"caption":"Transgene S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/b02550a51f9ea845f3d0a2f8e8732f54"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hHUgKHeBCUxRhZSnR5g0nA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b02550a51f9ea845f3d0a2f8e8732f54","width":300,"height":78}},"lazy":false},{"type":"text","content":"TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses","length":119,"tagName":"p"},{"type":"text","content":"Results reinforce TG4050 potential as an individualized cancer immunotherapy","length":76,"tagName":"p"},{"type":"text","content":"Strasbourg, France, January 9, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the preprint publication on medRxiv of a comprehensive analysis of both the clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine (INTV).The manuscript is now available on medRxiv - a preprint platform that enables early scientific visibility by sharing research ahead of journal peer review. In parallel, the article has been submitted to a peer-reviewed journal and is currently under evaluation.","length":698,"tagName":"p"},{"type":"text","content":"TG4050: an individualized therapeutic cancer vaccine shows 100% two-year disease-free survival as monotherapy in the adjuvant treatment of operable head and neck cancers ","length":169,"tagName":"p"},{"type":"text","content":"Despite the availability of current treatments, including immune checkpoint inhibitors, about one-third of patients with head and neck squamous cell carcinoma (HNSCC) experience recurrence within two years after surgery. Transgene’s trial with TG4050 was designed to assess whether inducing neoantigen-specific T-cell responses following treatment with an INTV encoding up to 30 predicted tumor neoantigens delivered via a Modified Ankara Virus (MVA) vector could help reduce the risk of relapse.","length":496,"tagName":"p"},{"type":"text","content":"Half of the part...